FDA
-
-
-
-
-
-
-
Celcuity reports positive Phase 3 trial results for gedatolisib in breast cancer
-
-
-
-
-
-
-
Celcuity Inc. Reports Release of Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
-
-
-
-
-
-
-
The $170B Survival Race: Why Big Pharma is Snapping Up Late-Stage Cancer Tech
-
-
-
-
-
-
-
Celcuity increases term loan facility to $500 million
-
-
-
-
-
-
-
Celcuity (CELC) Presents Overall Survival Data from Phase 1b Study Evaluating Gedatolisib in Combination with Palbociclib and Endocrine Therapy
-
-
-
-
-
-
-
Celcuity Inc. Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
-
-
-
-
-
-
-
Celcuity Inc. Reports Fourth Quarter and Full Year 2021 Financial Results, Pivotal Phase 3 Trial Design for Gedatolisib in the Treatment of Advanced Breast Cancer, and Business Updates
-
322,993 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

